Inhibition of RIP2/RICK/CARDIAK activity by pyridinyl imidazole inhibitors of p38 MAPK

Molecular and Cellular Biochemistry

Volumn 268, Issue 1-2, 2005, Pages 129-140

  Argast, Gretchen M ^a   Fausto, Nelson ^b   Campbell, Jean S ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Inhibitor; LPS; p38; RIP2; Signal transduction

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 NITROPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 (2 AMINO 4 PYRIMIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; BINDING PROTEIN; HISTONE H3; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MYELIN BASIC PROTEIN; RECEPTOR INTERACTING PROTEIN 2; THREONINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; IN VITRO STUDY; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SEQUENCE HOMOLOGY; WESTERN BLOTTING;

CELL LINE; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASE 2; SUBSTRATE SPECIFICITY;

EID: 14244262138     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11010-005-3701-0     Document Type: Article

References (34)

1. Frevel MA, Bakheet T, Silva AM, Hissong JG, Khabar KS, Williams BR: P38 Mitogen-activated protein kinase-dependent and -independent signaling of mRNA stability of AU-rich element-containing transcripts. Mol Cell Biol 23: 425-436, 2003 10.1128/MCB.23.2.425-436.2003
2. Dong C, Davis RJ, Flavell RA: Signaling by the JNK group of MAP kinases. c-jun N-terminal Kinase. J Clin Immunol 21: 253-257, 2001
3. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Keys JR, Landvatter SW, Strickler JE, McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL, Young PR: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372: 739-746, 1994
4. Clerk A, Sugden PH: The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs). FEBS Lett 426: 93-96, 1998 10.1016/S0014-5793(98)00324-X
5. Lali FV, Hunt AE, Turner SJ, Foxwell BM: The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J Biol Chem 275: 7395-7402, 2000 10.1074/jbc.275.10.7395
6. Huang M, Wang Y, Collins M, Gu JJ, Mitchell BS, Graves LM: Inhibition of nucleoside transport by p38 MAPK inhibitors. J Biol Chem 277: 28364-28367, 2002 10.1074/jbc.C200321200
7. Borsch-Haubold AG, Pasquet S, Watson SP: Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. J Biol Chem 273: 28766-28772, 1998
8. Hall-Jackson CA, Goedert M, Hedge P, Cohen P: Effect of SB 203580 on the activity of c-Raf in vitro and in vivo. Oncogene 18: 2047-2054, 1999 10.1038/sj.onc.1202603
9. Kalmes A, Deou J, Clowes AW, Daum G: Raf-1 is activated by the p38 mitogen-activated protein kinase inhibitor, SB203580. FEBS Lett 444: 71-74, 1999 10.1016/S0014-5793(99)00034-4
10. LoGrasso PV, Frantz B, Rolando AM, O'Keefe SJ, Hermes JD, O'Neill EA: Kinetic mechanism for p38 MAP kinase. Biochemistry 36: 10422-10427, 1997 10.1021/bi9706778
11. Young PR, McLaughlin MM, Kumar S, Kassis S, Doyle ML, McNulty D, Gallagher TF, Fisher S, McDonnell PC, Carr SA, Huddleston MJ, Seibel G, Porter TG, Livi GP, Adams JL, Lee JC: Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Biol Chem 272: 12116-12121, 1997 10.1074/jbc.272.18.12116
12. Lisnock J, Tebben A, Frantz B, O'Neill EA, Croft G, O'Keefe SJ, Li B, Hacker C, de Laszlo S, Smith A, Libby B, Liverton N, Hermes J, LoGrasso P: Molecular basis for p38 protein kinase inhibitor specificity. Biochemistry 37: 16573-16581, 1998 10.1021/bi981591x
13. Wang Z, Canagarajah BJ, Boehm JC, Kassisa S, Cobb MH, Young PR, Abdel-Meguid S, Adams JL, Goldsmith EJ: Structural basis of inhibitor selectivity in MAP kinases. Structure 6: 1117-1128, 1998
14. Wilson KP, McCaffrey PG, Hsiao K, Pazhanisamy S, Galullo V, Bemis GW, Fitzgibbon MJ, Caron PR, Murcko MA, Su MS: The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem Biol 4: 423-431, 1997
15. Eyers PA, Craxton M, Morrice N, Cohen P, Goedert M: Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem Biol 5: 321-328, 1998
16. Gum RJ, McLaughlin MM, Kumar S, Wang Z, Bower MJ, Lee JC, Adams JL, Livi GP, Goldsmith EJ, Young PR: Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket. J Biol Chem 273: 15605-15610, 1998
17. Inohara N, del Peso L, Koseki T, Chen S, Nunez G: RICK, a novel protein kinase containing a caspase recruitment domain, interacts with CLARP and regulates CD95-mediated apoptosis. J Biol Chem 273: 12296-12300, 1998
18. McCarthy JV, Ni J, Dixit VM: RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase. J Biol Chem 273: 16968-16975, 1998 1:CAS:528:DyaK1cXkt12ntrw%3D
19. Thome M, Hofmann K, Burns K, Martinon F, Bodmer JL, Mattmann C, Tschopp J: Identification of CARDIAK, a RIP-like kinase that associates with caspase-1. Curr Biol 8: 885-888, 1998
20. Humke EW, Shriver SK, Starovasnik MA, Fairbrother WJ, Dixit VM: ICEBERG: A novel inhibitor of interleukin-1beta generation. Cell 103: 99-111, 2000
21. Navas TA, Baldwin DT, Stewart TA: RIP2 is a Raf1-activated mitogen-activated protein kinase kinase. J Biol Chem 274: 33684-33690, 1999
22. Stehlik C, Hayashi H, Pio F, Godzik A, Reed JC: CARD6 is a modulator of NF-kappa B activation by Nod1- and Cardiak-mediated pathways. J Biol Chem 278: 31941-31949, 2003
23. Chin AI, Dempsey PW, Bruhn K, Miller JF, Xu Y, Cheng G: Involvement of receptor-interacting protein 2 in innate and adaptive immune responses. Nature 416: 190-194, 2002 1:CAS:528:DC%2BD38XisFSgsr4%3D
24. Kobayashi K, Inohara N, Hernandez LD, Galan JE, Nunez G, Janeway CA, Medzhitov R, Flavell RA: RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 416: 194-199, 2002 1:CAS:528:DC%2BD38XisFSgsrw%3D
25. Wu JC, Merlino G, Fausto N: Establishment and characterization of differentiated, nontransformed hepatocyte cell lines derived from mice transgenic for transforming growth factor alpha. Proc Natl Acad Sci USA 91: 674-678, 1994
26. EC Webb M Dixon 1997 Enzymes Academic Press Inc New York
27. Gallagher TF, Seibel GL, Kassis S, Laydon JT, Blumenthal MJ, Lee JC, Lee D, Boehm JC, Fier-Thompson SM, Abt JW, Soreson ME, Smietana JM, Hall RF, Garigipati RS, Bender PE, Erhard KF, Krog AJ, Hofmann GA, Sheldrake PL, McDonnell PC, Kumar S, Young PR, Adams JL: Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg Med Chem 5: 49-64, 1997
28. Jackson JR, Bolognese B, Hillegass L, Kassis S, Adams J, Griswold DE, Winkler JD: Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther 284: 687-692, 1998
29. Davies SP, Reddy H, Caivano M, Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105, 2000 10.1042/0264-6021:3510095
30. Beyaert R, Cuenda A, Vanden Berghe W, Plaisance S, Lee JC, Haegeman G, Cohen P, Fiers W: The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. Embo J 15: 1914-1923, 1996
31. Lisnock J, Tebben A, Frantz B, O'Neill EA, Croft G, O'Keefe SJ, Li B, Hacker C, de Laszlo S, Smith A, Libby B, Liverton N, Hermes J, LoGrasso P: Molecular basis for p38 protein kinase inhibitor specificity. Biochemistry 37: 16573-16581, 1998 10.1021/bi981591x
32. Meylan E, Martinon F, Thome M, Gschwendt M, Tschopp J: RIP4 (DIK/PKK), a novel member of the RIP kinase family, activates NF-kappa B and is processed during apoptosis. EMBO Rep 3: 1201-1208, 2002
33. Godl K, Wissing J, Kurtenbach A, Habenberger P, Blencke S, Gutbrod H, Salassidis K, Stein-Gerlach M, Missio A, Cotten M, Daub H: An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci USA 100: 15434-15439, 2003
34. Eyers PA, van den IP, Quinlan RA, Goedert M, Cohen P: Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580. FEBS Lett 451: 191-196, 1999